AU Patent

AU2011205164B2 — Compositions, suitable for oral administration, comprising a triazolo (4, 5-d) pyrimidin derivate

Assigned to AstraZeneca AB · Expires 2014-02-06 · 12y expired

What this patent protects

C:\NRPonbNDCC\RBR3792709_I.DOC44 /2011 - 15 Abstract The present invention relates to pharmaceutical compositions and more particularly to a pharmaceutical composition containing the compound { IS-[la, 2a, 30 (1S*,2R*),5p]}-3 5 (7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(pro…

USPTO Abstract

C:\NRPonbNDCC\RBR3792709_I.DOC44 /2011 - 15 Abstract The present invention relates to pharmaceutical compositions and more particularly to a pharmaceutical composition containing the compound { IS-[la, 2a, 30 (1S*,2R*),5p]}-3 5 (7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5. d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane- 1,2-diol.

Drugs covered by this patent

Patent Metadata

Patent number
AU2011205164B2
Jurisdiction
AU
Classification
—
Expires
2014-02-06
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.